MK-677 Results and Timelines: What Studies Report

Questions about MK-677 "results" assume a body of literature made up of timed efficacy studies in healthy adults. The published record is narrower than that. It consists of one large randomized controlled trial in an older clinical population, isolated case reports describing individuals who self-administered the compound, a rodent study of somatic growth, and analytical chemistry work in horses designed to detect the compound rather than to measure any benefit. This page summarises what those papers measured, in which model, and over what period. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or laboratory testing.

What MK-677 is, in the terms the papers use

MK-677 (also written MK-0677, ibutamoren) is described in the literature as an orally active growth hormone secretagogue — a compound studied for its ability to stimulate endogenous growth hormone release and downstream insulin-like growth factor I (IGF-I) signalling. It is not an approved medicine in the United States; where it appears in commerce it is generally labelled research-use-only, and it has been studied as an analytical target in anti-doping contexts, including hair testing in horses after oral administration (PMID 36354265). That regulatory position matters when reading outcome claims: there is no approved-label indication, dosing schedule or expected response curve to compare published findings against.

The studies on record, and what each one measured

The largest human trial: twelve months, and a negative primary result

The most substantial human dataset in this verified set came from a multicentre randomized, placebo-controlled trial in patients with mild-to-moderate Alzheimer's disease, in which researchers assigned oral MK-677 25 mg daily or placebo for 12 months and reported no clinical effect on the rate of disease progression (PMID 19015485). The trial's title states the conclusion plainly: a growth hormone secretagogue given for a year did not slow progression in that population (PMID 19015485).

Two features of that result are frequently lost when the compound is discussed in terms of "how long until results." First, the study was designed around clinical endpoints in a neurodegenerative disease, not around body composition, strength, sleep or appetite. A negative finding on cognitive progression says nothing about other outcomes that were never the trial's primary question. Second, the trial nonetheless demonstrated the general principle that a measurable change in the growth hormone/IGF-I axis — the pharmacological signal the compound was selected for — did not translate into the clinical benefit the investigators had hypothesised over a full year of daily dosing (PMID 19015485). Surrogate biochemical movement and clinical outcome are separate questions, and the literature separates them.

Why a twelve-month endpoint schedule is not a personal timeline

When a paper states that participants were followed for 12 months, that figure describes the trial's observation window and analysis plan (PMID 19015485). It is not an estimate of when an individual would notice anything, and it is not a claim that changes accumulate steadily across that period. Group-level trial designs are built to detect average differences between arms at prespecified timepoints; they are not designed to forecast the trajectory of any single participant, and the published reports do not provide per-person response curves.

Case reports: detailed measurement, no generalisable effect size

A case report in Experimental Physiology documented one individual who self-administered LGD-4033 together with MK-677, and researchers measured body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content across that period of use (PMID 36303408). The value of that report lies in its depth of measurement — including muscle tissue analysis, which almost no self-administration report includes — and its limits are equally clear from its design.

• Sample size of one. A single participant provides no variance estimate, no control condition and no basis for an effect size that could be applied to anyone else (PMID 36303408).
• Two compounds at once. Because the individual used a selective androgen receptor modulator alongside MK-677, no change documented in the report can be attributed to MK-677 alone (PMID 36303408).
• Uncontrolled context. Training, nutrition, sleep and product composition were not experimentally fixed, and self-administered material is not verified to the standard of trial supply.

These constraints are why methodologists treat case reports as hypothesis-generating. The report described what happened in one person under uncontrolled conditions; it did not establish what happens to people in general, and the authors published it as a case description rather than as an efficacy finding (PMID 36303408).

Animal work: growth in rodents, detection in horses

In the preclinical literature, a study in Yonsei Medical Journal examined the effect of the orally active growth hormone secretagogue MK-677 on somatic growth in rats, and the authors reported growth-related outcomes in that rodent model (PMID 30450851). Rodent growth studies are informative about mechanism and about whether a compound engages the growth axis at all, but growth physiology in a young rat differs substantially from adult human endocrinology, and dosing in milligrams per kilogram of body weight in rodents does not translate arithmetically to human exposure.

The equine work had a different purpose again. Investigators administered MK-0677 orally to horses and then developed and applied methods to detect the compound in hair, reporting successful detection following oral administration (PMID 36354265). That study was built for regulatory and anti-doping analysis. It demonstrates systemic exposure and incorporation into keratinised tissue over time; it measured no performance, body-composition or clinical outcome at all (PMID 36354265).

Adverse events reported with MK-677: What Studies Report

Safety information in this verified set comes from two very different sources. The randomized trial in Alzheimer's disease collected safety data across 12 months of daily oral dosing alongside its efficacy endpoints (PMID 19015485), which is the appropriate design for estimating how often events occur relative to placebo.

Separately, a 2025 case report in BMJ Case Reports described hepatotoxicity induced by MK-677, documenting liver injury in an individual case (PMID 40675653). A single case report cannot establish incidence — it cannot say how often liver injury occurs, in whom, or at what exposure — but it does establish that clinicians have described and published such a presentation in association with the compound (PMID 40675653). The 2022 case report similarly included circulating biomarker measurement as part of its documentation of one individual's use (PMID 36303408).

Taken together, the adverse-event literature in this set is thin and skewed toward case-level reporting, which captures unusual or severe presentations rather than typical experience. Rare-event detection requires large, systematically monitored cohorts, and those do not exist for non-clinical use of this compound.

Why the literature does not support an outcome timeline

Several structural gaps prevent this evidence base from answering the question of how quickly anything changes:

1. Population mismatch. The one large controlled trial studied older adults with Alzheimer's disease over 12 months (PMID 19015485), a population whose endocrine and clinical baseline differs from that of healthy adults.
2. Endpoint mismatch. The trial's endpoints were disease-progression measures (PMID 19015485); the equine study's endpoint was analytical detection (PMID 36354265); the rodent study's endpoint was somatic growth (PMID 30450851). None of these is the outcome usually implied by informal "results" language.
3. No dose-ranging in healthy adults. Nothing in this verified set established a dose-response relationship for non-clinical outcomes, so no exposure can be linked to any magnitude of change.
4. Confounded case data. The most detailed human measurement came from a single person using two compounds simultaneously (PMID 36303408).
5. Publication and reporting bias. Case reports appear in the literature because something noteworthy happened, whether beneficial measurement or harm, which makes them a poor basis for estimating averages.

The honest reading is that individual outcomes are not predictable from this literature. Where a paper reported a duration, that duration belongs to the study protocol. Where a paper reported a change, that change belongs to the model and population studied — 12 months of daily dosing in a clinical trial population (PMID 19015485), one self-administering individual (PMID 36303408), rats (PMID 30450851) or horses (PMID 36354265).

What stronger evidence would look like

To answer questions about magnitude and time course, the field would need prospective, randomized, placebo-controlled trials in clearly defined populations, with verified drug supply, more than one dose level, prespecified measurement timepoints, validated body-composition and functional endpoints, and systematic collection of laboratory safety data including hepatic markers — the domain flagged by the published hepatotoxicity case (PMID 40675653). Until such trials exist, summaries can describe what researchers measured and what they reported, and nothing beyond that. Anyone weighing information about this compound for a personal or clinical situation should discuss it with a licensed physician who can review individual history and laboratory results.

References

• Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (Neurology, 2008)
• Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats (Yonsei Medical Journal, 2018)
• LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report (Experimental Physiology, 2022)
• Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration (Drug Testing and Analysis, 2023)
• Hepatotoxicity induced by MK-677 (BMJ Case Reports, 2025)